|Stem Cell Therapy Statement
Casimir Knight, president of SMA Europe, discusses Stem Cell Therapy for SMA Type 1 children.
To read his statement and find out more, plea ...
03 04 2013
SMA Biomarker Study in Immediate Postnatal Development
A new study on SMA Biomarkers is starting in the US.
Dr. Kold of Ohio State University is leading this study, which will take place in 15 l ...
23 01 2013
SMN gene delivery to the spinal cord decreases disease severity in mice
Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. ...
08 01 2013
Repligen in licensing agreement with Pfizer Inc.
It was announced today that Repligen has entered into an exclusive, worldwide licensing agreement with pharmaceutical company Pfizer Inc. for its S ...
03 01 2013